Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Triple Negative Breast Neoplasms × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 HER2-expressing Advanced Solid Tumors 1 HER-2 Positive Colorectal Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1 Brain Neoplasms 1

Interventions

pembrolizumab 30 Nivolumab 14 Paclitaxel 13 Carboplatin 13 Cyclophosphamide 9 sacituzumab govitecan 7 Cisplatin 7 Capecitabine 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 Magnetic Resonance Spectroscopy 5 Biopsy 5 camrelizumab 4 atezolizumab 4 Specimen Handling 4 Ipilimumab 4 Interleukin-2 4 Injections 4 Immune Checkpoint Inhibitors 4 Gemcitabine 4 Docetaxel 4 toripalimab 3 talazoparib 3 fludarabine 3 avelumab 3 Immunoglobulin G 3 Everolimus 3 Clinical Trials, Phase II as Topic 3 spartalizumab 2 seviteronel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03805399 2022-08-10

FUTURE

Fudan University

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡